Clinical Trials on Children With Low Vision in Australia

Total 12 results

Novartis

Completed

A 12 Month Core Study to Assess the Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema and a 24 Month Open-label Extension Study (RESTORE)

Diabetic Macular Edema

Greece, Belgium, Spain, France, Netherlands, Australia, Canada, Germany, Hungary, Italy, Switzerland, Turkey, United Kingdom
Medical University of Vienna

Withdrawn

Amblyopia and Neurovascular Coupling in the Retina of Humans

Amblyopia | Regional Blood Flow

Austria
Bayer

Recruiting

The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema

Visual Impairment | Neovascular Age-related Macular Degeneration (nAMD) | Diabetic Macula Edema (DME)

Germany, Canada, Denmark, France, Italy, Saudi Arabia, Switzerland, Australia, Finland, Netherlands, Sweden, Norway, United Arab Emirates, Japan, United Kingdom
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema (KESTREL)

Diabetic Macular Edema

United States, Austria, Japan, Australia, Spain, Canada, Israel, Netherlands, Italy, United Kingdom, Portugal, Colombia, Puerto Rico, Argentina
Medical University Innsbruck

Unknown

Validation of Kujala German

Validation of Kujala Score German Version in Patients With Patellofemoral Instability and Scheduled MPFL-reconstruction

Austria
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia

Pathological Myopia

Germany, India, Japan, Turkey, Austria, Switzerland, Italy, Lithuania, Hungary, France, Slovakia, United Kingdom, Korea, Republic of, Portugal, Hong Kong, Canada, Singapore, Spain, Latvia, Poland
Novartis Pharmaceuticals

Completed

Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRYSTAL)

Central Retinal Vein Occlusion | Macular Edema

Greece, Hungary, Turkey, Australia, Austria, Netherlands, United Kingdom, Italy, Spain, Ireland, Portugal, Slovakia, Canada, Switzerland, Czech Republic, Poland, Denmark, Sweden
Novartis Pharmaceuticals

Terminated

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion (RAVEN)

Central Retinal Vein Occlusion

China, Czechia, Germany, Russian Federation, Turkey, United States, Australia, Canada, Spain, United Kingdom, Thailand, Israel, Netherlands, Italy, Hungary, France, Greece, Puerto Rico, Malaysia, Japan
Novartis Pharmaceuticals

Terminated

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion (RAPTOR)

Branch Retinal Vein Occlusion

China, Austria, Czechia, Russian Federation, Taiwan, United Kingdom, Canada, Japan, United States, France, Israel, Germany, Italy, Hong Kong, Spain, Denmark, Slovakia, Puerto Rico, Switzerland
Novartis Pharmaceuticals

Completed

A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies

Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3 | Squamous Lung Cancer With FGFR1 Amplification | Bladder Cancer With FGFR3 Mutation or Fusion | Advanced Solid Tumors With FGFR1 Amplication | Advanced Solid Tumors With FGFR2 Amplication | Advanced Solid Tumors With FGFR3 Mutation

France, Spain, Taiwan, Germany, Netherlands, Singapore, United States, Australia, Korea, Republic of, Thailand, Israel, Italy, Turkey, Austria
FibroGen
AstraZeneca; Astellas Pharma Inc

Terminated

Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden

Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts)

United States, Australia, Belgium, Germany, Israel, Italy, Korea, Republic of, Russian Federation, Spain, United Kingdom, France, Turkey, Canada, Denmark, India, Poland
Sanford Health
National Ataxia Foundation; Beyond Batten Disease Foundation; Pitt Hopkins Research... and other collaborators

Recruiting

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford (CoRDS)

Mitochondrial Diseases | Retinitis Pigmentosa | Myasthenia Gravis | Eosinophilic Gastroenteritis | Multiple System Atrophy | Leiomyosarcoma | Leukodystrophy | Anal Fistula | Spinocerebellar Ataxia Type 3 | Friedreich Ataxia | Kennedy Disease | Lyme Disease | Hemophagocytic Lymphohistiocytosis | Spinocerebellar Ataxia... and other conditions

United States, Australia

Clinical Trials on Children With Low Vision in Australia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Brazil

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations